---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-034191"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:06:18.406566+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health presents data showing personalized VNS nearly doubles HRV in 60% of participants

## Summary
- Data from Feinstein Institute collaboration presented at Sixth Bioelectronic Medicine Summit.
- Personalized ncVNS frequency optimized HRV change; no single frequency universally dominant.
- 60% of participants (responders) saw raw HRV nearly double on average post-stimulation.
- Normalized HRV increased 2.67x, indicating enhanced vagal tone and improved autonomic balance.
- Company believes findings support non-invasive devices for inflammatory, cardiac, neurologic disorders.

## SEC filing metadata
- accession: 0000950170-25-034191
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025034191/0000950170-25-034191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025034191/tivc-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-034191
- JSON: https://secwatch.observer/filing/0000950170-25-034191.json
- Plain text: https://secwatch.observer/filing/0000950170-25-034191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.